Showing 1921-1930 of 2736 results for "".
- FDA Clears Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting Systemhttps://modernaesthetics.com/news/fda-clears-bimini-health-techs-dermapose-access-office-based-fat-harvesting-system/2472922/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access system creates a new pr
- Demystified: Your Insurance Coverage During COVID-19https://modernaesthetics.com/news/demystified-your-insurance-coverage-during-covid-19/2472913/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i
- David Long Tapped As Cynosure's Global Chief Financial Officerhttps://modernaesthetics.com/news/david-long-is-cynosures-global-chief-financial-officer/2472908/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its
- News You Can Use: UAB Infographic Depicts How Long COVID-19 Lasts on Surfaceshttps://modernaesthetics.com/news/news-you-can-use-uab-infographic-depicts-how-long-covid-19-lasts-on-surfaces/2472906/A virologist and an infectious diseases physician at the
- FDA Clears Wontech’s Sandro Dual Laserhttps://modernaesthetics.com/news/fda-clears-wontechs-sandro-dual-laser/2472905/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- Special Report: Dr. Jonathan Kaplan Offers Coronavirus Overviewhttps://modernaesthetics.com/news/special-report-dr-jonathan-kaplan-offers-coronavirus-overview/2472894/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less collateral damag
- Dermatologists React to Threat of Coronavirus Pandemichttps://modernaesthetics.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic-1/2472891/Reports about COVID-19 are causing many dermatologists and aesthetic physicians to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a &l
- Cynosure Launches Potenza RF Microneedling Devicehttps://modernaesthetics.com/news/cynosure-launches-potenza-rf-microneedling-device/2472886/The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device. The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency)
- Get Ready for Allergan's New DTC Juvéderm Lips Campaignhttps://modernaesthetics.com/news/get-ready-for-allergans-new-dtc-juvederm-lips-campaign/2472882/Allergan is launching its new direct-to-consumer campaign for Juvéderm lips with ads and creative deploying across TV, social media, and digital advertising. As part of the new campaign, New York City-based facial plastic surgeon Dara Liotta, MD, reality television personality Au
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.